DUBLIN, July 13, 2017 /PRNewswire/ --
The "Microbiome Technologies: Energizing Pharma and Life Sciences" report has been added to Research and Markets' offering.
Microbiome science has become a key area of research for biopharmaceutical companies. At present, there are multiple start-ups emerging, which are focusing their resources towards the development of novel therapeutics as well as diagnostic/screening technologies and services. In an era of personalized medicine, the current trajectory of growth witness across the microbiome industry parallels, the growth that took place across genomics.
Some of the milestones that have occurred in the microbiome field are the application of next generation screening towards identifying and assessing microbial levels within the human gut. Using these microbial biomarkers, scientists are pushing the boundaries by identifying novel drug targets as well as probiotic or prebiotic products that could aid in balancing the microbial ecosystem within the human body.
Key Topics Covered:
1. Executive Summary
- Interest Across The Microbiome Rapidly Rising
- The Past, Present & Future of Human Microbiomics
- Microbiome Product Diversity And Segmentation
2. Technology Snapshot
- Technology Overview: Therapeutics
- Technology Overview: Over-the-counter
- Technology Overview: Diagnostic Products & Services
3. Impact of Microbiome Innovations
- More than 50% of all Microbiome Research is Focused Towards the GI
- Multiple Diseases Have Unmet Therapeutics Needs
- Clostridium difficile Threat Increasing due to Increasing Antibiotic use
- Inflammatory Bowel Disease Another Large Unmet Area of Urgent Need
- Skin Disorders Have Found A New Age Therapeutic Solution
- Lifestyle Disorders Could Also Be Controlled Through the Microbiome
- Immune-Microbiome A New Avenue In Cancer Research
- OTC Microbiome Products Have Numerous Consumer Target Segments
- OTC Microbiome Products Promote A Balanced Micro-ecosystem
- Documented Usage of Probiotics Across Human Health is Diverse
4. Advances in Microbiome Innovations
- Largest Contribution Towards the Microbiome Product Landscape Comes from Probiotic Drugs
- Microbiome Therapeutics are Developed to with a Strategic Technical Design Based Approach
- OTC Microbiome Products - Key Segments
- OTC Microbiome Products - Some Probiotics/Prebiotic Stakeholders
- Current Microbiome Company Ecosystem Segmented by Technology Focus
- Microbiome Stakeholders Mergers, Acquisitions & Partnerships Snapshot
5. Company Innovation Profiles
- Approach
- Seres Health (Seres Therapeutics)
- AvidBiotics
- Rebiotix
- Ritter Pharmaceutical
- Vedanta Biosciences
- C3 Jian
6. Opportunity Evaluation & Roadmap
- Regional Analysis of OTC Health Innovations
- Regional Analysis of Diagnostic/Services Innovations
- Technology Roadmap
7. Growth Opportunities
- Growth Opportunity: Microbiome
- Major Growth Opportunities for Microbiome
- Strategic Imperatives for Microbiome Technology Stakeholders
For more information about this report visit https://www.researchandmarkets.com/research/7k6ljf/microbiome
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
